Diltiazem drip
Pro Research Analysisby 
Searched over 200M research papers for "diltiazem drip"
The Efficacy and Safety of Diltiazem Drip in Various Cardiac Conditions
Intravenous Diltiazem for Atrial Fibrillation and Congestive Heart Failure
Intravenous diltiazem has been shown to be highly effective in managing rapid atrial fibrillation or flutter in patients with moderate to severe congestive heart failure. In a multicenter, randomized, double-blind, placebo-controlled study, 95% of patients responded to diltiazem, compared to none in the placebo group. The treatment led to a significant reduction in heart rate, with 97% of patients achieving a therapeutic response .
Diltiazem in Hypertrophic Cardiomyopathy
A pilot randomized trial assessed the use of diltiazem in pre-clinical hypertrophic cardiomyopathy (HCM) mutation carriers. The study found that diltiazem was safe and potentially beneficial in early left ventricular remodeling. Specifically, it improved left ventricular end-diastolic diameter and stabilized the left ventricular thickness-to-dimension ratio, suggesting a promising role in modifying disease expression in HCM .
Diltiazem as Adjunctive Therapy in Acute Myocardial Infarction
In the context of acute myocardial infarction (AMI), diltiazem has been evaluated as an adjunctive therapy to tissue plasminogen activator (t-PA). Although it did not significantly affect coronary artery patency or left ventricular function, diltiazem reduced the rate of death, reinfarction, or recurrent ischemia from 41% to 13% at 35 days. This suggests a protective effect against early post-infarction ischemia and reinfarction .
Prevention of Reinfarction in Non-Q-Wave Myocardial Infarction
Diltiazem has also been effective in preventing reinfarction and severe angina in patients with non-Q-wave myocardial infarction. A multicenter, double-blind, randomized study showed a 51.2% reduction in reinfarction rates and a 49.7% reduction in refractory postinfarction angina with diltiazem treatment .
Attenuation of Cardiovascular Response to Tracheal Intubation
Diltiazem has been found to attenuate the cardiovascular response to laryngoscopy and tracheal intubation. Patients treated with diltiazem showed significantly reduced increases in mean arterial pressure and rate pressure product compared to those who received saline, indicating its efficacy in managing hypertensive responses during intubation .
Termination of Reentrant Supraventricular Tachycardia
In patients with reentrant supraventricular tachycardia, intravenous diltiazem has proven to be highly effective. A placebo-controlled, randomized, double-blind study demonstrated that 90% of patients treated with diltiazem achieved conversion to sinus rhythm, compared to only 19% in the placebo group. The median time to tachycardia termination was just 2 minutes .
Impact on Myocardial Infarct Size and Cardiac Function
Diltiazem has shown potential in reducing ischemic injury in acute myocardial infarction. Studies indicate that it may decrease perfusion defect scores and improve ejection fraction recovery, suggesting a cardioprotective effect . Additionally, in patients with idiopathic dilated cardiomyopathy, diltiazem improved cardiac function, exercise capacity, and subjective well-being without adverse effects on transplant listing-free survival .
Conclusion
Diltiazem drip has demonstrated significant efficacy and safety across various cardiac conditions, including atrial fibrillation, hypertrophic cardiomyopathy, acute myocardial infarction, and supraventricular tachycardia. Its ability to reduce heart rate, prevent reinfarction, and improve cardiac function makes it a valuable therapeutic option in cardiology. Further research and clinical trials are warranted to explore its full potential and optimize its use in different patient populations.
Sources and full results
Most relevant research papers on this topic